| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
CYSTIC FIBROSIS |
1 Department of Medicine, University of Manchester, Manchester Royal Infirmary, Manchester M13 9WL, UK
2 Adult Cystic Fibrosis Centre, South ManchesterUniversity Hospitals NHS Trust, Wythenshawe Hospital, ManchesterM23 9LT, UK
3 Belfast Adult Cystic Fibrosis Centre, Belfast City Hospital, Belfast, UK
4 MRC Biostatistics Unit and Research and Development Unit, Papworth Hospital, Cambridge CB3 8RE, UK
5 Clinical Radiology, Imaging Science and Biomedical Engineering, University of Manchester, Manchester M13 9PT, UK
Correspondence to:
Correspondence to:
Dr C S Haworth
Adult Cystic Fibrosis Centre, Papworth Hospital, Papworth Everard, Cambridge, CB3 8RE, UK; charles.haworth{at}papworth.nhs.uk
Background: Proinflammatory cytokines stimulate osteoclast activity and this could lead to increased bone resorption in patients with cystic fibrosis. The aim of this study was to determine whether markers of systemic inflammation are related to changes in bone mineral content (BMC) in adults with cystic fibrosis.
Methods: Total body BMC was assessed by dual energy x ray absorptiometry in 100 patients (54 male) of mean (SD) age 25.6 (7.1) years and forced expiratory volume in 1 second (FEV1) 61.8 (24.1)% predicted on recruitment to the study and 1 year later. Blood was also taken at these time points to measure markers of systemic inflammation.
Results: After 1 year BMC had reduced by 16.1 (62.1) g, p = 0.01; (0.6 (2.8)%). The change in BMC was related to mean levels of interleukin (IL)-6 (rs = –0.39, p<0.001) and C reactive protein (rs = –0.34, p = 0.002), intravenous antibiotic use (rs = –0.27, p = 0.006) and oral corticosteroid use (rs = –0.20, p = 0.045). Urinary markers of osteoclast activity were also related to IL-6 (rs = 0.27, p = 0.02). Multiple linear regression revealed that IL-6 (coefficient –2.2 (95% CI –3.4 to –1.0) per pg/ml, p = 0.001), colonisation with Burkholderia cepacia (coefficient –46.8 (95% CI –75.5 to –18.1), p = 0.002), and annual change in BMI (coefficient 15.4 (95% CI 3.6 to 27.2) per kg/m2, p = 0.011) were independently significant predictors of annual change in BMC.
Conclusions: These data suggest a pathophysiological mechanism by which chronic pulmonary infection results in bone loss in patients with cystic fibrosis.
Abbreviations: BMC, bone mineral content; BMD, bone mineral density; BMI, body mass index ; BSAP, bone specific alkaline phosphatase; CRP, Creactive protein; FEV1, forced expiratory volume in 1 second ; IL-6, interleukin 6
Keywords: cystic fibrosis; bone mineral content; cytokines; interleukin-6
Relevant Article
Thorax 2004 59: 545.
This article has been cited by other articles:
|
|
 |
|
  A. Papaioannou, C. C. Kennedy, A. Freitag, G. Ioannidis, J. O'Neill, C. Webber, M. Pui, Y. Berthiaume, H. R. Rabin, N. Paterson, et al. Alendronate Once Weekly for the Prevention and Treatment of Bone Loss in Canadian Adult Cystic Fibrosis Patients (CFOS Trial) Chest, October 1, 2008; 134(4): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Shead, C. S. Haworth, E. Gunn, D. Bilton, M. A. Scott, and J. E. Compston Osteoclastogenesis during Infective Exacerbations in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., August 1, 2006; 174(3): 306 - 311. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
